Overview

Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to demonstrate efficacy and safety of quetiapine fumarate (SEROQUEL) compared with placebo in the treatment of adolescent patients with schizophrenia.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Treatments:
Quetiapine Fumarate
Criteria
Inclusion Criteria:

- Patient is able to provide written assent and the parents or legal guardian of the
patient is able to provide written informed consent before beginning and study related
procedures

- Patient has a documented clinical diagnosis of schizophrenia

- Patient's parent or legal guardian will be able to accompany the patient at each
scheduled study visit

Exclusion Criteria:

- Patients (female) must not be pregnant or lactating

- Patients with a known intolerance or lack of response to previous treatment with
quetiapine

- Patients who have previously participated in this study